Cómo proceder ante personal sanitario alérgico a la vacuna de ARNm contra el COVID-19 / How to deal with healthcare workers allergic to COVID-19 mRNA vaccine

Notifican al Servicio de Prevención y Riesgos Laborales el caso de una enfermera de 37 años que refiere rinorrea acuosa y prurito generalizado 10-15 minutos tras la administración de la primera dosis vacunal generada por BioNTech/Pfizer. Presenta: eritema facial, habón maxilar y constantes normales. ¿Cómo debe actuar el Servicio de Prevención y Riesgos Laborales (SPRL) frente a una trabajadora sanitaria que sufre una reacción alérgica a la vacuna de ARNm contra el COVID-19?Este caso clínico llama la atención sobre medidas preventivas habituales como la vacunación pero también sobre otras como la colaboración entre diferentes servicios hospitalarios, el manejo y diagnóstico por Alergología, seguimiento del Servicio de Prevención y notificación de efectos vacunales adversos por Farmacología Clínica.La coordinación entre estos servicios resulta fundamental para el correcto manejo de trabajadores afectados por reacciones adversas frente a la primera dosis vacunal contra el COVID-19 pudiendo quedar vacunados y protegidos. (AU)

The Occupational Risk and Prevention Service is notified the case of a 37-year-old nurse who reported watery rhinorrhea and generalized itching 10-15 minutes after first dose of the vaccine produced by BioNTech/Pfizer’s administration. She presents: facial erythema, maxillary wheal and normal constants. How should the Occupational Risk and Prevention Service should deal with a health worker who suffers an allergic reaction to the mRNA vaccine against COVID-19?This clinical case draws attention to common preventive measures such as vaccination, but also to others such as collaboration between different hospital services, management and diagnosis by Allergology, follow-up by the Occupational Risk and Prevention Service and notification of adverse vaccine effects by Clinical Pharmacology.Coordination between these services is essential for the correct management of workers affected by adverse reactions to the first vaccine dose against COVID-19, being the workers able to be vaccinated and protected. (AU)

Influence of soluble and insoluble cyclodextrin polymers on drug release from hydroxypropyl methylcellulose tablets.

BACKGROUND: The influence of beta-cyclodextrin (beta-CD) polymers on drug release from hydroxypropyl methylcellulose (HPMC) matrices has not been reported in the literature. AIM: The influence of monomeric beta-CD and both soluble and insoluble beta-CD polymers on drug release from tablets containing either 30% or 50% hydroxypropyl methylcellulose has been studied using diflunisal (DF) as model drug. METHOD: The DF-beta-CD inclusion complex (1:1 M) was prepared by coevaporation and characterised using X-ray diffraction, differential thermal analysis, and IR spectroscopy. The dissolution assays were performed according to the USP paddle method. RESULTS: The incorporation of beta-CD in the complexed form increases drug release from hydroxypropyl methylcellulose tablets in comparison with the physical mixture because of the better solubilization of the drug. The soluble polymer promotes drug release to a higher extent than the physical mixture with monomeric beta-CD, but the insoluble polymer, which is itself a hydrogel, gives rise to the most retarded release profile, probably by retention of the drug in its structure. The formulations containing physical mixtures with either beta-CD or the soluble polymer present an optimum adjustment to zero-order release kinetics, and the inclusion complex followed non-Fickian diffusion according to the Korsmeyer-Peppas model. CONCLUSION: The release profile of DF from a HPMC matrix can be modulated in different ways by the use of either monomeric or polymeric beta-CD.